Initiation And Titration Instructions Prepare For DUOPA Treatment Over time, additional changes may be necessary based on the patient’s clinical response and tolerability. Once no further adjustments are required to the DUOPA Morning Dose, Continuous Dose, or Extra Dose, this dosing regimen should be administered daily. Administration of frequent extra doses may cause or worsen dyskinesias. The extra dose frequency should be limited to one extra dose every 2 hours. If the amount of the extra dose needs to be adjusted, it is typically done in 0.2 mL increments. The extra dose function should be set at 1 mL (20 mg of levodopa) when starting DUOPA. Titration of the dose as needed based on individual clinical response and tolerability.ĭUOPA has an extra dose function that can be used to manage acute “Off” symptoms that are not controlled by the Morning Dose and the Continuous Dose administered over 16 hours.Calculation and administration of the DUOPA starting dose (Morning Dose and Continuous Dose) for Day 1.Conversion of patients to oral immediate-release carbidopa-levodopa tablets in preparation for DUOPA treatment.
Treatment with DUOPA is initiated in 3 steps : At the end of the daily 16-hour infusion, patients will disconnect the pump from the PEG-J and take their night-time dose of oral immediate-release carbidopa-levodopa tablets. The maximum recommended daily dose of DUOPA is 2000 mg of the levodopa component (i.e., one cassette per day) administered over 16 hours. The daily dose is determined by individualized patient titration and composed of: DOSAGE AND ADMINISTRATION DUOPA Daily DoseĭUOPA is administered over a 16-hour infusion period.
The inactive ingredients in DUOPA are carmellose sodium and purified water.ĭUOPA® is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. Its empirical formula is C 9H 11NO 4, and its structural formula is: It is designated chemically as (2S)-2-Amino-3-(3,4-dihydroxyphenyl) propanoic acid. Levodopa is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. The 4.63 mg/mL of anhydrous carbidopa is equivalent to 5.0 mg/mL of carbidopa. The content of carbidopa in DUOPA is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
It is designated chemically as (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid monohydrate. You may report side effects to FDA at 1-80.ĭUOPA is a combination of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an aromatic amino acid.Ĭarbidopa is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.2. For more information, ask your doctor or pharmacist.Ĭall your doctor for medical advice about side effects. These are not all the possible side effects of Duopa. Tell the doctor if you have any side effect that bothers you or that does not go away. The most common side effects of Duopa include: Get medical help right away, if you have any of the symptoms listed above. numbness or weakness in your hands or feet,.suddenly falling asleep after being alert,.uncontrolled muscle movements in your face (chewing, lip smacking, frowning, tongue movement, blinking or eye movement),.cough, pain, swelling, redness, warmth, or oozing around the tube in your stomach wall,.swelling of your face, lips, tongue, or throat,.What are the possible side effects of Duopa?ĭuopa may cause serious side effects including: It is not known if Duopa is safe and effective in children. Duopa may be used alone or with other medications.ĭuopa belongs to a class of drugs called Decarboxylase Inhibitors Antiparkinson Agents Dopamine Precursors. Duopa is a prescription medicine used to treat the symptoms of Advanced Parkinson Disease.
0 kommentar(er)
